ES2053810T3 - Nuevos anticuerpos quimericos. - Google Patents

Nuevos anticuerpos quimericos.

Info

Publication number
ES2053810T3
ES2053810T3 ES88810898T ES88810898T ES2053810T3 ES 2053810 T3 ES2053810 T3 ES 2053810T3 ES 88810898 T ES88810898 T ES 88810898T ES 88810898 T ES88810898 T ES 88810898T ES 2053810 T3 ES2053810 T3 ES 2053810T3
Authority
ES
Spain
Prior art keywords
antibodies
derivatives
chemical
processes
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88810898T
Other languages
English (en)
Inventor
Norman Dr Hardman
Laura Lee Dr Gill
Winter Ronald F J Dr De
Kathrin Wagner
Christoph Dr Heusser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888800077A external-priority patent/GB8800077D0/en
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of ES2053810T3 publication Critical patent/ES2053810T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A ANTICUERPOS MONOCLONALES QUIMERICOS HUMANOS/MURIDOS CON ALTA ESPECIFICIDAD Y AFINIDAD PARA EL ANTIGENO CANCERINO - EMBRIONICO HUMANO (CEA), SUS DERIVADOS, PROCESOS PARA LA PREPARACION DE ESTOS ANTICUERPOS Y SUS DERIVADOS, CODIFICANTE ADN PARA CADENAS LIGERAS Y PESADAS DE ESTOS ANTICUERPOS, PROCESOS PARA LA PREPARACION DE DICHOS ADN, LINEAS DE CELULAS DE MAMIFEROS QUE PRODUCEN Y SEGREGAN LOS ANTICUERPOS Y PROCESOS PARA LA PREPARACION DE DICHAS LINEAS DE CELULAS. LOS ANTICUERPOS QUIMERICOS Y SUS DERIVADOS SE USAN CON FINES CLINICOS IN VITRO E IN VIVO ESPECIALMENTE PARA LA DIAGNOSIS DEL CANCER, PARA LA LOCALIZACION E IMAGEN IN VIVO DE TUMORES, PARA TERAPIA, P.E. APARATO SITEDIRECTED DE CITOTOXINAS, Y OBJETIVOS SIMILARES. LA INVENCION SE REFIERE TAMBIEN A OBJETOS DE ENSAYO Y COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS ANTICUERPOS MONOCLONALES QUIMERICOS Y/O SUS DERIVADOS.
ES88810898T 1988-01-05 1988-12-28 Nuevos anticuerpos quimericos. Expired - Lifetime ES2053810T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888800077A GB8800077D0 (en) 1988-01-05 1988-01-05 Novel chimeric antibodies
GB888820099A GB8820099D0 (en) 1988-01-05 1988-08-24 Novel chimeric antibodies

Publications (1)

Publication Number Publication Date
ES2053810T3 true ES2053810T3 (es) 1994-08-01

Family

ID=26293262

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88810898T Expired - Lifetime ES2053810T3 (es) 1988-01-05 1988-12-28 Nuevos anticuerpos quimericos.

Country Status (10)

Country Link
EP (1) EP0323806B1 (es)
JP (1) JPH02154696A (es)
AU (1) AU625613B2 (es)
DE (1) DE3879452T2 (es)
DK (1) DK172444B1 (es)
ES (1) ES2053810T3 (es)
GR (1) GR3007853T3 (es)
HK (1) HK156695A (es)
IE (1) IE62440B1 (es)
PT (1) PT89384B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407392B2 (en) * 1987-12-31 1998-10-28 Tanox Biosystems, Inc. UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES
IL89491A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3900534A1 (de) * 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US5081235A (en) * 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
US5580774A (en) * 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen
AU632843B2 (en) * 1989-08-10 1993-01-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin
AU634314B2 (en) * 1989-11-13 1993-02-18 Green Cross Corporation, The Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991014438A1 (en) * 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB2276169A (en) * 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1992022653A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9317423D0 (en) * 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
EP0753065B1 (en) 1994-03-29 2003-05-14 Celltech Therapeutics Limited Antibodies against e-selectin
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
AU4373197A (en) * 1996-09-19 1998-04-14 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
EP1598671A1 (en) * 1999-10-28 2005-11-23 Agensys, Inc. Diagnosis and therapy of cancer using SGP28-related molecules
EP1572131B1 (en) 2002-10-08 2016-07-06 Immunomedics, Inc. Antibody therapy
EP2210903A1 (en) * 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations

Also Published As

Publication number Publication date
DK2189D0 (da) 1989-01-04
DK2189A (da) 1989-07-06
DK172444B1 (da) 1998-07-27
EP0323806B1 (en) 1993-03-17
IE62440B1 (en) 1995-02-08
EP0323806A1 (en) 1989-07-12
GR3007853T3 (es) 1993-08-31
IE890019L (en) 1989-07-05
DE3879452D1 (de) 1993-04-22
PT89384A (pt) 1990-02-08
HK156695A (en) 1995-10-13
AU625613B2 (en) 1992-07-16
AU2759588A (en) 1989-07-06
DE3879452T2 (de) 1993-07-15
JPH02154696A (ja) 1990-06-14
PT89384B (pt) 1993-09-30

Similar Documents

Publication Publication Date Title
ES2053810T3 (es) Nuevos anticuerpos quimericos.
ES2061730T3 (es) Nuevos anticuerpos.
Peng et al. Purification of immunogenic heat shock protein 70–peptide complexes by ADP-affinity chromatography
Kawashima et al. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells
BR0008772A (pt) Polipeptìdeo isolado, proteìna de fusão, molécula de polinucleotìdeo isolado, vetor de expressão, célula cultivada, anticorpo, processos para produzir uma proteìna e um anticorpo para um polipeptìdeo, para estimular uma resposta imunológica em um mamìfero, para expandir células hematopoiéticas e progenitores de células hematopoiéticas, para reduzir a proliferação de células b ou t neoplásicas e para detectar a presença de rna de ligando zalfa11 e de ligando zalfal11 em uma amostra biológica
BR9707379A (pt) Anticorpo humano isolado ácido nucleico isolado vetor recombinante de expressão célula hospedeira processo para sintetizar um anticorpo humano que se liga á TNF Alfa humano composição farmacéutica processo para inibir á atividade do TNF humano e uso do anticorpo
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
DE3751809D1 (de) Intraoperative erstellung des befundes und tumor-therapie mittels endoskop
ES2803217T3 (es) Antígeno de superficie de células de cáncer de próstata para el diagnóstico
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
CN101845438B (zh) 20种肿瘤特异相关的基因与产物的癌症的灵敏诊断与相关治疗
Steele et al. The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens
Epenetos et al. An immunohistological study of testicular germ cell tumours using two different monoclonal antibodies against placental alkaline phosphatase
BR9913942A (pt) Polinucleotìdeo e polipeptìdeo isolado, vetor de expressão, célula cultivada, constructo de dna codificador de uma proteìna de fusão, processos de produção de uma proteìna, de fusão de um polipeptìdeo e de um anticorpo para o polipeptìdeo e de detecção, em uma amostra de teste, da presença de um modulador da atividade da proteìna zalpha11 e de um ligante de receptor zalpha11 dentro de uma amostra de teste, e, anticorpo
Moore et al. Comparative studies of a near-tetraploid and a near-diploid line of Ehrlich's ascites tumor propagated in vivo and in vitro II. Cytology and transplantability
AU445936B2 (en) Reagent formulations for assaying biological specimens and methods of preparing and using same
Nakamura et al. Spontaneous remission of a non-small cell lung cancer possibly caused by anti-NY-ESO-1 immunity
ES2101695T3 (es) Haptoglobina relacionada con el cancer (hpr).
Garin-Chesa et al. Cell surface molecules of human melanoma. Immunohistochemical analysis of the gp57, GD3, and mel-CSPG antigenic systems.
Neumann et al. A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4+ and CD8+ T-cell as well as B-cell responses
Ju Lee et al. Identification of novel HLA-A* 0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer
Broers et al. Novel antigens characteristic of neuroendocrine malignancies
Hellström et al. Melanoma‐associated antigen p97 continues to be expressed after prolonged exposure of cells to specific antibody
Ng et al. Molecular heterogeneity and shedding of a high-molecular-mass melanoma-associated antigen identified with monoclonal antibodies.
Newhall et al. Dunning rat prostate tumors and cultured cell lines fail to express human prostate carcinoma‐associated antigens

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 323806

Country of ref document: ES